Anthem Biosciences has received markets regulator Securities and Exchange Board of India’s (SEBI's) clearance to raise funds through initial public offering (IPO). The proposed IPO is entirely an offer for sale (OFS) worth Rs 3,395 crore by promoters, investors and other selling shareholders.
Since the IPO is entirely an OFS, the company will not receive any funds from the issue and the proceeds will go to the selling shareholder. JM Financial, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue.
Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem's business also manufactures and sale of specialty ingredients. It also manufactures and sells complex specialised fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, and biosimilars.